Huahai Pharmaceutical announced that its wholly-owned subsidiary Pharmaceutical Technology has received the drug registration certificate for Riociguat Tablets approved and issued by the National Medical Products Administration. The specifications include 0.5 mg, 1 mg, and 2.5 mg, with a registration classification of Category 4 chemical drugs, deemed to have passed the consistency evaluation. The drug is used to treat chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. The original drug was developed by Bayer, approved for marketing in the United States in 2013, and approved for import in China in 2017 under the brand name Adempas. According to data from Menet, the domestic market sales of this drug are projected to be approximately 150 million yuan in 2025, and the company's cumulative R&D investment is about 7.43 million yuan.
Bayer AG NAHuahai's generic Riociguat approval in China introduces competition to Bayer's branded Adempas in that market.
Zhejiang Huahai Pharmaceutical Co LtdWholly-owned subsidiary received NMPA drug registration certificate for Riociguat Tablets, allowing it to market the drug in China.
